Finance

March 31 Quick Takes: Cowen leads €47M addition to AM-Pharma's C round; plus Zucara, CellFe, Zentalis and Shanghai Junshi

AM-Pharma raises $52M series C extension  AM-Pharma B.V. raised €47 million ($51.7 million) in an additional close of its series C round, bringing the total funds raised in the round to €163 million. The round...

With new $450M fund, Gilde is latest European firm to aim for bigger holdings in earlier-stage investments

With its largest venture and growth capital fund to date, a $450 million vehicle, Gilde Healthcare is the latest European VC seeking to take bigger stakes in start-ups than it previously had sought, sometimes investing...

ElevateBio raises $170M, plans additions to portfolio with six clinical programs by 2021

With $170 million in fresh cash, cell and gene therapy manufacturing and R&D company ElevateBio believes it can shepherd its portfolio companies to bring six clinical programs into clinical testing by next year -- and...

SutroVax heading to clinic with potential competitor to Pfizer’s Prevnar 13

With its new $110 million series D round, SutroVax is preparing for its first clinical trial that could test its 24-valent pneumonia vaccine against Prevnar 13 -- or a next-generation version. RA Capital and Janus...

March 25 Quick Takes: Temasek leads Abbisko’s $70M C round; plus IASO and Regenacy

Abbisko raises $70M series C  Abbisko Therapeutics Co. Ltd. raised $70 million in a series C round, bringing the total funds raised by the cancer company to $140 million since its founding in 2016. Temasek...

March 24 Quick Takes: Apexigen brings series C to $123M; plus Nanjing F&S, FCA and Asieris

Apexigen boosts series C with $65M extension   Apexigen Inc. added $65 million to its 2018 series C, bringing the round to $123 million. The extension was led by Decheng Capital and new investor Oceanpine...

Design debuts with $45M series A, portfolio against repeat expansions

Design Therapeutics emerged from stealth Friday with a $45 million series A and a portfolio of bifunctional small molecules to treat degenerative disorders caused by nucleotide repeat expansions, starting with Friedreich's ataxia. SR One led...

COVID stocks spike as market volatility continues

As the broader markets continue to tumble amidst the COVID-19 pandemic, several biotechs at the center of the race to develop countermasures have seen their valuations swing wildly since the crisis began to unfold in...

Strong investor demand for InnoCare on HK exchange despite pandemic concerns

Despite ongoing turbulence in the global financial markets, strong demand by local investors enabled InnoCare to price its IPO on the Hong Kong exchange's biotech chapter at the top of its proposed range, valuing the...

March 17 Quick Takes: Tempus, Circle, Immatics, Exuma, CFIUS

Tempus raises $100M series G  Tempus raised $100 million in a series G round, bringing the total raised by the company to over $600 million since its founding in 2015. Baillie Gifford, Franklin Templeton, NEA,...

With strengthened balance sheet, Keros is latest biotech looking to test IPO market

Keros’ $56 million series C round early this month appears to be the last stepping stone towards an IPO intended to fund its ongoing clinical work. Despite the volatile public markets, the hematological and musculoskeletal...

Sigilon nears first clinical test of cell shielding tech with $80M series B

With its $80.3 million series B round, Sigilon is planning to bring the first of its shielded cell therapies into the clinic, while also advancing toward INDs on four other programs. Canada Pension Plan Investment...

Nurix raises $120M in week’s second major protein degradation financing

Nurix’s $120 million funding round is the second fund-raising for a targeted protein degradation company in excess of $100 million this week. Along with Kymera’s $102 million round, Nurix’s deal reflects the promise investors see...

Cratering market spoils Imara’s NASDAQ debut

Imara managed to make its public debut Thursday after raising $75.2 million in an IPO; however, the hemoglobinopathy company’s shares were immediately swept up in Thursday’s market turmoil. Imara Inc. (NASDAQ:IMRA) slipped $1 to $15...

Harbour backs first registrational trials with $75M B+ round

Harbour BioMed raised $75 million in a series B+ round to advance its clinical antibody programs, including three registrational trials planned for this year. New investors SK Holdings, Greater Bay Area Fund, Efung Capital, Zheshang...